Altered Brain Tissue Volumes With Valproate Treatment for Schizophrenia

Read full text Summarise with VIRAT
Authors: Tom Cawood, Olivia K. Harrison, Meghan McIlwain, Robert R. Kydd, Bruce R. Russell
Cited by: 0
References: 70

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Schizophrenia is a debilitating psychiatric condition that affects ≈0.5% of the global population. Some people with schizophrenia do not respond to first‐line antipsychotics and are prescribed clozapine; this is termed treatment‐resistant schizophrenia (TRS). When clozapine is ineffective for patients with TRS, and concomitant antipsychotics or mood stabilisers are required, this is termed ultra‐TRS (UTRS). Patients with UTRS are often prescribed augmentation therapy with mood stabilisers such as valproate to relieve residual symptoms. However, to date, the relationship between valproate and brain structure in people with schizophrenia has not been well described. Using magnetic resonance imaging, we found significant decreases in whole brain and white matter volumes in participants taking valproate compared to those taking clozapine without valproate. Further analyses revealed hypertrophy of grey matter in the cerebellum. This research indicates that using valproate augmentation in people with schizophrenia may alter white matter volumes and fractional anisotropy (FA) and grey matter density in the cerebellum and brainstem when compared to those receiving clozapine.

Fields of Study & Subjects

Schizophrenia research and treatment Treatment of Major Depression Mental Health and Psychiatry

Publication details

Journal / source
Journal of the Royal Society of New Zealand
Volume
56
Issue
2
Publication date
23 March 2026
Language
EN